|
30 Jan 2023 |
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
|
|
26 Jan 2023 |
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
|
|
25 Jan 2023 |
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
|
|
25 Jan 2023 |
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
|
|
20 Jan 2023 |
LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer
|
|
18 Jan 2023 |
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
|
|
18 Jan 2023 |
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
|
|
16 Jan 2023 |
Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®
|
|
13 Jan 2023 |
Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
|
|
10 Jan 2023 |
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
|
|
06 Jan 2023 |
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
|
|
06 Jan 2023 |
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
|
|
04 Jan 2023 |
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
|
|
28 Dec 2022 |
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
|
|
27 Dec 2022 |
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
|
|
22 Dec 2022 |
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
|
|
21 Dec 2022 |
Novel, personalized immunotherapy platform designed to achieve Trifecta of anti-cancer activity using unique bi-shRNA DNA-based plasmid and patient's own tumor tissue
|
|
20 Dec 2022 |
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
|
|
15 Dec 2022 |
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met
|
|
15 Dec 2022 |
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
|
|
12 Dec 2022 |
Amphera Announces Clinical Updates of MesoPher Cell Therapy
|
|
09 Dec 2022 |
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
|
|
08 Dec 2022 |
Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
|
|
07 Dec 2022 |
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
|
|
05 Dec 2022 |
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
|
